Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Proteomic profiling of bone marrow in AML

Christopher Hourigan • 16 Jun 2020
EHA 2020
Acute Myeloid Leukemia Leukemia

Christopher Hourigan, DM, DPhil, FACP, FRCP, of the National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, describes a novel proteomic approach to characterize the non-cellular compartment of the bone marrow microenvironment in acute myeloid leukemia (AML) and outlines how this provides mechanistic insights into AML etiology as well as guiding efforts in future targeted therapies and immunotherapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Christopher Hourigan

1:39
How can MRD guide treatment of AML?
Christopher Hourigan • 4 Jun 2022
1:11
Current role of MRD in AML
Christopher Hourigan • 4 Jun 2022
1:09
Pre-MEASURE: patients with AML in complete remission but high risk of relapse following alloHCT
Christopher Hourigan • 4 Jun 2022
2:50
Conditioning intensity and genomics: relapse after allogeneic transplant in MDS
Christopher Hourigan • 16 Jun 2020

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals